Sign In
Buy RHHBY
$49.06
-0.130 (-0.264%)
At Close: Jun 03, 2026
Basel, 7 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus ne
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo�
FDA approves Roche's Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
11:45am, Tuesday, 04'th Feb 2025
Basel, 04 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment o
Roche Q4 Earnings Review: Solid All-Court Performance, But Quiet On GLP-1 Progress
01:01pm, Friday, 31'st Jan 2025
Roche Holding AG released its Q4 and full-year 2024 earnings yesterday. I'm broadly encouraged, although I wanted to hear more about the three GLP-1 agonist assets. Sales were up ~7%, and core EPS gre
Basel, 31 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® anti-HER2/neu (4B5) Rabbit
Roche Holding AG (RHHBY) Q4 2024 Earnings Call Transcript
02:04pm, Thursday, 30'th Jan 2025
Roche Holding AG (OTCQX:RHHBY) Q4 2024 Earnings Conference Call January 30, 2025 8:00 AM ET Company Participants Thomas Schinecker - CEO Alan Hippe - Chief Financial & Information Officer Teresa Graha
Roche's 2024 Sales and Earnings Beat, Key Drugs Perform Well
01:16pm, Thursday, 30'th Jan 2025
RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.
Roche CEO: We had a strong 2024 and expect momentum to carry into 2025
07:00am, Thursday, 30'th Jan 2025
Thomas Schinecker, the CEO of Roche, discusses the Swiss company's full-year earnings.
Roche sees high single-digit core profit growth in 2025
01:08am, Thursday, 30'th Jan 2025
Swiss drugs and diagnostics company Roche said on Thursday it is targeting an increase in core 2025 earnings per share in a high single-digit percentage range, when adjusted for currency swings.
Basel, 30 January 2025 Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics. Excluding COVID-19, Group sales increased by 9%.
Change to the Roche Enlarged Corporate Executive Committee
01:00am, Wednesday, 29'th Jan 2025
Basel, 29 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company as Chief Digital Technology Officer (CDTO), reporting to Group CEO, Thomas
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the overall survival (OS) analysis of t
Basel, 28 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from the overall survival (OS) analysis of the phase III INAVO120 study investigating ItovebiTM (in
Basel, 27 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from year two of the EMBARK trial, a global, randomised, double-blind phase III study of Elevidys�
Basel, 22 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance and Clinical Laboratory Improvement Amendments
